This BIOTECH Has 10x Upside Potential
2 extracted signals · 2 resolved · 0 still active
MarketBeatIndependent analyst profile- Source published
- 24 Sept 2026, 01:02 UTC
- Recorded by Tahlil Plus
- 24 Sept 2026, 03:49 UTC
AI-generated source summary
The analysis focuses on three biotechnology stocks: Kodiak Sciences (KOD), Capricorn Therapeutics (CAPR), and Invivid (IVVD). Kodiak Sciences (KOD) is currently trading at $32.71, with a year-to-date gain of approximately 250%, pushing its market cap to over $2 billion. The stock is showing a bullish trend, with a target price of $53.71 and a calculated failure bound of $25.00. Capricorn Therapeutics (CAPR) is trading at $9.07, down 70% year-to-date, but has seen a recent uptick of about 27.8% in the last month. Despite its recent bearish trend, the analysis suggests a potential bullish reversal, targeting $8.00, with a failure bound of $10.50. The company is under FDA review for its Biologics License Application (BLA) for Deramiocel, with a target date of November 22nd, 2026, which was previously August 22nd. Invivid (IVVD), trading at $0.76, is described as a penny stock with a market cap of approximately $247 million. The company has two products in clinical stage trials and is generating revenue. Analysts have set a consensus price target of $8.00, suggesting a potential gain of over 840% from its current trading price. The predicted trend for IVVD is bullish, with a failure bound set at $0.50.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
MarketBeat
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.